Breaking News

Everest Medicines, Sinovent, SinoMab Enter Global BTK Inhibitor Mfg. Pact

To develop, produce and commercialize XNW1011, a covalent reversible BTK inhibitor, globally for the treatment of renal diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Everest Medicines has entered into an exclusive licensing agreement with Suzhou Sinovent Pharmaceuticals Co., Ltd. and SinoMab BioScience to develop, produce and commercialize XNW1011 (SN1011 by SinoMab), a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, globally for the treatment of renal diseases.    Everest will pay Sinovent and SinoMab $12 million upfront and as much as $549 million in development, regulatory, and commercial milestones, as well as royalties on global sa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters